Zydus Lifesciences Limited has received final approval for Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA), as per an exchange filing.
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma.
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
The group now has 354 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Bombay HC Refuses Unconditional Stay On ₹250.82 Crore Arbitral Award In Favour Of L&T-STEC JV Against MMRCL
Bombay HC Orders Holdout Developers To Vacate Ghatkopar's Parekh Market Premises, Clears Path For Redevelopment
Mumbai News: Dog Stranded In Juhu Beach Waters For Three Days, Rescued After Massive Effort
Maharashtra Politics: 'BJP’s WhatsApp Groups Linked To Central War Room, Not Used for Surveillance,' Chandrashekhar Bawankule Clarifies
